Verici Dx (Verici Dx) Current Deferred Revenue : $0.00 Mil (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Verici Dx's current deferred revenue for the quarter that ended in Jun. 2023 was $0.00 Mil.

Verici Dx Current Deferred Revenue Historical Data

The historical data trend for Verici Dx's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Current Deferred Revenue Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Current Deferred Revenue

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Current Deferred Revenue	-	-	-	-	-

Verici Dx Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Verici Dx's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines